Best Longevity Ingredients for Adults: What the Research Says

Why this list, and what it leaves out

There are dozens of compounds with some claim to "longevity ingredient" status. Most have thin evidence; a few have substantial published human or animal RCT bases. This article covers the five with the deepest peer-reviewed research as of 2026: urolithin A, calcium alpha-ketoglutarate (Ca-AKG), spermidine, fisetin, and nicotinamide mononucleotide (NMN). Two reviews provide useful big-picture context on where the field is — Partridge et al. in Nature Reviews Drug Discovery on the quest to slow ageing through drug discovery ¹ and Guarente et al. in Cell Metabolism on human trials of longevity-targeted compounds ².

We exclude compounds with weaker peer-reviewed evidence (rapamycin is a prescription drug and outside the supplement scope; metformin is also prescription; resveratrol has interesting mechanism work but a less-clean clinical-RCT picture in humans; CoQ10 is more of a foundational mitochondrial cofactor than a longevity intervention; glycine is interesting but still earlier-stage in the longevity-specific literature).

A note on framing: this is informational content using structure/function language only. The compounds discussed are dietary supplements; the regulatory disclaimer at the foot of the article spells out the full set of limits. Talk to a licensed physician before starting a supplement, especially if you are on prescription pharmaceuticals.

1. Urolithin A — the most-published

Urolithin A is the gut-bacterial metabolite produced when ellagitannins (in pomegranates, walnuts, some berries) reach the gut microbiome. Direct supplementation bypasses the microbiome-dependence issue (not everyone's gut produces urolithin A efficiently from precursors).

Mechanism. Mitophagy activator — selective autophagy of damaged mitochondria. The pivotal mechanism paper, Ryu et al. 2016 in Nature Medicine, demonstrated mitophagy induction and lifespan prolongation in C. elegans alongside increased muscle function in rodents ³. Subsequent reviews lay out the broader picture ⁴.

Human evidence. Andreux et al. 2019 in Nature Metabolism — randomized, double-blind, placebo-controlled safety study in older adults at 250 mg, 500 mg, and 1000 mg daily over 28 days; reported no significant adverse-event differences vs. placebo and a molecular signature consistent with improved mitochondrial and cellular health ⁵. Liu et al. 2022 in JAMA Network Open — four-month RCT in older adults; muscle endurance and mitochondrial-health biomarker improvements ⁶. Singh et al. 2022 in Cell Reports Medicine — four-month RCT at 500 mg/day in middle-aged adults; muscle-strength and exercise-performance improvements ⁷. A 2024 systematic review synthesizes the body of work ⁸.

Dose. Most-studied human dose is 500 mg once daily. 250 mg and 1000 mg also tested.

Verdict. The strongest peer-reviewed human-clinical evidence in the longevity-supplement category as of 2026.

2. Calcium alpha-ketoglutarate (Ca-AKG) — striking mouse data, early human data

Ca-AKG is the calcium salt of alpha-ketoglutarate, a Krebs-cycle intermediate.

Mechanism. AKG sits at a metabolic hub: it is a substrate for several dioxygenase enzymes that regulate DNA and histone methylation; it intersects with amino-acid metabolism; and it has been shown to inhibit ATP synthase and TOR signaling, both of which have been implicated in lifespan regulation ⁹.

Animal evidence. Asadi Shahmirzadi et al. 2020 in Cell Metabolism reported that AKG, administered late in life, extended median lifespan and compressed morbidity in aging mice ¹⁰. The morbidity-compression result is particularly notable — the treated mice not only lived longer but spent more of their remaining life healthy.

Human evidence. A 2022 review in Trends in Endocrinology and Metabolism summarized the AKG dietary supplementation literature in humans ¹¹. The human-RCT base is much earlier-stage than urolithin A. Long-term lifespan-extension trials in humans have not been completed for any supplement, AKG included.

Dose. Most human supplementation protocols dose Ca-AKG at 1–3 g/day, often split.

Verdict. The mouse data is striking; the human picture is younger and still being developed. Reasonable inclusion in a multi-compound stack; not yet supported by the same depth of human RCT evidence as urolithin A.

3. Spermidine — mechanism breadth, smaller clinical base

Spermidine is a polyamine — a small organic molecule that induces autophagy across model systems. It is present in wheat germ, aged cheese, and several fermented foods at meaningful dietary levels.

Mechanism. Autophagy induction — the cellular process of recycling damaged proteins and organelles. The 2018 Science review by Madeo et al. covers spermidine in health and disease ¹²; the 2019 Cell Metabolism review on caloric restriction mimetics provides the broader context ¹³.

Mitochondrial relevance. A 2024 Sports Medicine review on mitochondria as nutritional targets to maintain muscle health and physical function during ageing covers the broader nutritional landscape including polyamines ¹⁴.

Human evidence. Smaller than for urolithin A or NMN. The mechanism is well-described; observational and pilot trial data exists; large randomized trials specifically powered for clinical longevity endpoints are less developed.

Dose. Typical human supplementation: 1–15 mg/day. Dietary sources (wheat germ, aged cheese) provide comparable amounts.

Verdict. Strong mechanism story across species; thinner randomized-human-trial base. Reasonable inclusion in a stack; not a standalone hero.

4. Fisetin — senolytic mouse data, early human

Fisetin is a flavonoid found in strawberries and other plants.

Mechanism. Senolytic — selective clearance of senescent cells. Senescent cells stop dividing but remain metabolically active and secrete inflammatory signals; they accumulate with age and contribute to chronic low-grade inflammation. Clearing them in animal models is associated with improved healthspan markers.

Animal evidence. Yousefzadeh et al. 2018 in EBioMedicine described fisetin as a senotherapeutic that extended health and lifespan in aged mice ¹⁵.

Human evidence. Early-stage. Senolytic dose-response in humans is an active research question. Some senolytic research protocols use "hit and run" dosing — high doses on intermittent schedules — rather than continuous daily intake; whether daily modest fisetin produces meaningful senolytic effects in humans remains an open question.

Dose. Mouse research translates approximately to ~10–20 mg/kg in humans; most commercial supplementation is much lower. Senolytic-protocol research in humans uses much higher pulse doses.

Verdict. Strong mechanism story in mice; the human picture is earlier-stage. Reasonable inclusion at modest daily doses; high-dose senolytic protocols are research territory.

5. NMN — NAD+ precursor, growing human data

NMN — nicotinamide mononucleotide — is a precursor in the NAD+ salvage pathway. NAD+ is a coenzyme used by sirtuins, PARPs, and several other classes of enzymes; NAD+ levels decline with age.

Mechanism. Raises NAD+ via the salvage pathway. NAD+ is required for sirtuin activity, which is implicated in mitochondrial biogenesis, DNA repair, and metabolic regulation.

Human evidence. Yi et al. 2023 in GeroScience — randomized, multicenter, double-blind, placebo-controlled dose-dependent safety and efficacy trial in healthy middle-aged adults ¹⁶. Yoshino et al. 2021 in Science — NMN increased muscle insulin sensitivity in prediabetic women ¹⁷.

Dose. Common doses are 250–500 mg/day; the Yi 2023 trial tested up to 900 mg/day with good tolerability.

Verdict. Strong and growing human-RCT base. Targets a different mechanism (NAD+ availability) than urolithin A (mitophagy) or AKG (Krebs cycle). Many people stack NMN with mitophagy- or AKG-focused supplements rather than viewing them as substitutes.

So which one should you take?

The honest answer depends on what you are trying to support and what you are willing to take. A few framings:

• If you want one supplement with the best-developed human evidence, urolithin A is the answer.
• If you want to target NAD+ availability specifically, NMN is the most-published option.
• If you want broader mitochondrial-quality-control support, a stack approach — urolithin A (mitophagy) plus Ca-AKG (Krebs cycle) plus spermidine (autophagy) — has the most mechanistic coverage.
• If you want senolytic support, fisetin is the most-published; serious senolytic protocols are still research territory.

We designed Vector Sapiens around the stack philosophy: cover mitophagy (urolithin A), Krebs cycle (Ca-AKG), autophagy (spermidine), and modest senolytic support (fisetin) in one daily formula. That is not the only valid configuration; NMN-first protocols are also defensible based on the published evidence.

What none of these can honestly claim:

• None has direct evidence of lifespan extension in humans. Long-term human lifespan trials have not been completed for any supplement.
• All target structure/function mechanisms — not therapeutic outcomes for any specific disease.
• Effect sizes in surrogate biomarkers (mitochondrial-DNA copy number, NAD+ levels, walking distance) do not perfectly predict clinical-outcome effects.
• Animal effect sizes, especially in mice, generally do not extrapolate quantitatively to humans.

Next steps

The companion mechanism deep-dive is the human longevity research guide, which covers each compound in more detail. The Vector Sapiens product page lists ingredient amounts and dosing for the multi-compound stack.